Fabry disease gene therapy regulatory update

Genzyme received U.S. Patent No. 6,066,626 covering in vivo administration of viral and non-viral vector gene therapy to treat Fabry disease. Genzyme General (GENZ, Cambridge, Mass.) submitted in Jun...